Notice to Withdraw the Centers for Disease Control and Prevention (CDC) as a Participating Organization from PAR-19-334 entitled "SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, R44) Clinical Trial Not Allowed"

Notice Number: NOT-OD-20-039

Key Dates
Release Date: December 6, 2019

Related Announcements

PAR-19-334

Issued by
National Institutes of Health (NIH)

Purpose

The purpose of this Notice is to withdraw the Centers of Disease Control and Prevention (CDC) as a Participating Organization from PAR-19-334 entitled SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, R44) Clinical Trial Not Allowed .

Effective immediately, the text of PAR-19-334 is modified as indicated below:

Part 1. Overview Information

Current Language
Participating Organization(s)
National Institutes of Health (NIH)
Centers for Disease Control and Prevention (CDC)

Modified Language:
Participating Organization(s)
National Institutes of Health (NIH)

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Purpose

Current language
The SBIR and STTR programs were reauthorized and extended through 2022 under Public Law 114-328, Section 1834 and Public Law 115-232, including the reauthorization of the Commercialization Readiness Pilot (CRP) Program to the NIH. This funding opportunity announcement (FOA) aims to re-implement the CRP Program at NIH and CDC. The goal of this FOA is to facilitate the transition of previously funded SBIR/STTR Phase II projects to the commercialization stage by providing additional support for later stage technical assistance activities not typically supported through Phase II or Phase IIB grants or contracts. Only those applicants who have recently received Phase II or Phase IIB funding from one of the participating NIH Institutes/Centers or CDC are eligible for this program, as described in Section III.1.

Modified language
The SBIR and STTR programs were reauthorized and extended through 2022 under Public Law 114-328, Section 1834 and Public Law 115-232, including the reauthorization of the Commercialization Readiness Pilot (CRP) Program to the NIH. This funding opportunity announcement (FOA) aims to re-implement the CRP Program at NIH. The goal of this FOA is to facilitate the transition of previously funded SBIR/STTR Phase II projects to the commercialization stage by providing additional support for later stage technical assistance activities not typically supported through Phase II or Phase IIB grants or contracts. Only those applicants who have recently received Phase II or Phase IIB funding from one of the participating NIH Institutes/Centers are eligible for this program, as described in Section III.1.

Current language
Scientific/Technical Scope
NIH and CDC ICs participating in this FOA may accept applications based on any topic within their mission or based on specific topics. While general topic areas are listed below, applicants should read the specific interests of the ICs carefully prior to submission.

Modified language
Scientific/Technical Scope
NIH ICs participating in this FOA may accept applications based on any topic within their mission or based on specific topics. While general topic areas are listed below, applicants should read the specific interests of the ICs carefully prior to submission.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Sean D. Griffiths, MPH
Science Policy Advisor
Manager, Small Business Innovation Research (SBIR) Program
Office of Technology and Innovation
Office of Science
Centers for Disease Control and Prevention (CDC)
Email: SGriffiths@cdc.gov